| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CFO, Secretary, Treasurer
2 companies
Tamara A Favorito is CFO, Secretary, Treasurer at VRDN, with reported holdings spanning 2 companies. Tamara A Favorito's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.7M at current prices.
Our model assigns Tamara A Favorito a middling insider score of 69/100, based on 3 past trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +29.5%.
Tamara A Favorito's largest disclosed position is in VRDN as CFO, Secretary, Treasurer, worth about $2.7M.
Tamara A Favorito has 20 Form 4 filings on record from August 2015 to July 2026, across 4 companies: Director at Artelo Biosciences (ARTL), 2026; Director at Zevra Therapeutics (ZVRA), 2022–2026; Director at TuHURA Biosciences (HURA), 2021–2023, and 1 more.
The 25 reported transactions were 14 option or other derivative awards, 4 option exercises, 4 tax withholdings and 3 open-market purchases.
Counted by filing, the open-market trades come to 3 purchases worth about $28K and no sales.
The largest open-market purchase was 3,175 shares of ZVRA at an average $7.79 on September 12, 2025, about $25K. Twelve months later ZVRA was up 55%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 3,175 | $7.79 | $24,718.01 | +441.6% | +8.3% | +55.0% | |
| Mar 17, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 519 | $4.82 | $2,502.36 | +259.5% | +22.7% | +25.0% | |
| May 20, 2022 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 200 | $4.87 | $974.00 | New | +12.9% | +8.4% |